Zynerba Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Zynerba Pharmaceuticals

16/05/2022 13:01

* Zynerba Pharmaceuticals Inc  ZYNE.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of 23 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Zynerba Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had risen by
about 12% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Zynerba Pharmaceuticals Inc shares had fallen by 58.3%
this
quarter and lost 70.3% so far this year.
    * The company reported a quarterly loss of $8.49 million.
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $8.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 16 at 12:00 p.m.  ​All
figures in US dollars unless otherwise stated